Bio-Techne Corporation
Bio-Techne Corporation
Your view on TECH
Overview
What the company does, where it operates, and who runs it.
About Bio-Techne Corporation
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Kim Kelderman
- Headquarters
- 614 McKinley Place N.E., Minneapolis, MN, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Kim Kelderman
- Headquarters
- 614 McKinley Place N.E., Minneapolis, MN, US
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics.
The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.
This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids.
The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications.
It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014.
Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Bio-Techne Corporation from FRC's valuation model, read against the market price. TECH last traded at $72.79, 66.2× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Bio-Techne Corporation. Starting points for Bio-Techne Corporation: P/E 66.2, EPS $1.10, beta 1.27 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Bio-Techne Corporation. Bio-Techne Corporation paid $0.40 per share over the last year — a 0.5% yield at the current $72.79 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Bio-Techne Corporation. Trailing twelve-month EPS for Bio-Techne Corporation stands at $1.10. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$67.18
average of 11 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy2
- Hold10
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Jun 2027 | Next YearFY Jun 2028 |
|---|---|---|---|---|
| Avg. estimate | $0.47 | $0.55 | $2.05 | $2.36 |
| Low estimate | $0.45 | $0.53 | $1.86 | $2.20 |
| High estimate | $0.49 | $0.57 | $2.20 | $2.49 |
| No. of analysts | 4 | 4 | 5 | 5 |
| Year-ago EPS | $0.46 | $0.53 | $1.16 | — |
| Growth | +2.2% | +3.3% | +77.0% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Jun 2027 | Next YearFY Jun 2028 |
|---|---|---|---|---|
| Avg. estimate | $308.75M | $327.10M | $1.27B | $1.40B |
| Low estimate | $305.21M | $324.01M | $1.25B | $1.39B |
| High estimate | $312.27M | $328.76M | $1.29B | $1.43B |
| No. of analysts | 5 | 5 | 9 | 7 |
| Year-ago revenue | $295.88M | $311.42M | $1.22B | — |
| Growth | +4.3% | +5.0% | +4.7% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0; as of Nov 18, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Bio-Techne Corporation. Bio-Techne Corporation has reported as a listed company since 1989. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- AAgilent Technologies, Inc.Medical - Diagnostics & Research$48.8B
- ALMRAlamar Biosciences, Inc.Biotechnology$2.1B
- BIOBio-Rad Laboratories, Inc.Medical - Devices$9.7B
- BRKRBruker CorporationMedical - Devices$9.3B
- DHRDanaher CorporationMedical - Diagnostics & Research$161.9B
- QGENQiagen N.V.Medical - Diagnostics & Research$10.3B
- RVTYRevvity, Inc.Medical - Diagnostics & Research$16.6B
- SEERSeer, Inc.Biotechnology$83M
More Biotechnology companies
- CDTTWCDT Equity Inc.NASDAQ$5,704
- CDXICardax, Inc.OTC$80
- CDXSCodexis, Inc.NASDAQ$116M
- CELCCelcuity Inc.NASDAQ$3.0B
- CELUCelularity Inc.NASDAQ$20M
- CELZCreative Medical Technology Holdings, Inc.NASDAQ$4M
- CEROCERo Therapeutics Holdings, Inc.OTC$45,803
- CEROWCERo Therapeutics Holdings, Inc.OTC
- CFRXQContraFect CorporationOTC$107
- CGEMCullinan Therapeutics, Inc.NASDAQ$617M
- CGENCompugen Ltd.NASDAQ$193M
- CGONCG Oncology, Inc. Common stockNASDAQ$7.6B
ETFs holding Bio-Techne Corporation
% of the fund
- VOOVanguard S&P 500 ETF$1.0T in assets0.02%
- VTIVanguard Total Stock Market ETF$689.2B in assets0.02%
- VBVanguard Small-Cap ETF$76.9B in assets0.14%
- RSPInvesco S&P 500 Equal Weight ETF$101.8B in assets0.20%
- GNOMGlobal X - Genomics & Biotechnology ETF$108M in assets4.55%
- MNANYLI Merger Arbitrage ETF$263M in assets3.46%
- FBTFirst Trust NYSE Arca Biotechnology Index Fund$3.0B in assets3.33%
- BBHVanEck Biotech ETF$536M in assets1.15%
Largest holders first, then the funds most concentrated in TECH.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Bio-Techne Corporation, and how their positions are changing. At a $11.43B market value, institutional positions materially move Bio-Techne Corporation's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Bio-Techne Corporation executives and directors. Shares of Bio-Techne Corporation have traded between $46.01 and $79.28 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
About this section
U.S. Senate disclosures naming Bio-Techne Corporation. Bio-Techne Corporation is a $11.43B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
About this section
U.S. House of Representatives disclosures naming Bio-Techne Corporation. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Bio-Techne Corporation. Coverage tracks Bio-Techne Corporation within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Bio-Techne Corporation.